| Abstrakt: |
A recent study conducted by Lausanne University Hospital and the University of Lausanne in Switzerland analyzed the real-life experience of chronic hepatitis C treatment in the country. The study included 3,088 patients with chronic hepatitis C who were treated with direct-acting antivirals (DAAs) between January 2015 and December 2019. The overall sustained virological response (SVR) rate, defined as undetectable HCV RNA at week 12 after the first course of DAA-based treatment, was 96.2%, with an increase over time. Factors associated with SVR included female sex, the use of the latest generation of pangenotypic DAA regimens, Caucasian origin, and genotype 1. On the other hand, the presence of active hepatocellular carcinoma (HCC), genotype 3, and increasing liver stiffness were associated with treatment failure. The study concluded that SVR rates increased over time, with the highest success rates observed after the introduction of the latest generation of pangenotypic DAA regimens. Active HCC, genotype 3, and increasing liver stiffness were identified as risk factors for DAA failure. [Extracted from the article] |
